MaxCyte

Yahoo Finance • 7 days ago

MaxCyte announces 34% workforce reduction to cut costs

* MaxCyte (NASDAQ:MXCT [https://seekingalpha.com/symbol/MXCT]) is implementing a restructuring plan that includes a 34% reduction in its global workforce, including EOR personnel. * The move is aimed at cutting operating expenses, stre... Full story

Yahoo Finance • 7 days ago

MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability

ROCKVILLE, Md., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-ge... Full story

Yahoo Finance • 2 months ago

Brooke William buys Maxcyte (MXCT) shares worth $64,500

Director William W. Brooke purchased 50,000 shares of MAXCYTE, INC. (NASDAQ:MXCT) common stock on August 13, 2025, at a price of $1.29 per share. The total value of the purchase was $64,500. Following the transaction, Brooke directly owns... Full story

Yahoo Finance • 2 months ago

MaxCyte stock rating downgraded to Neutral by BTIG on funding concerns

Investing.com - BTIG downgraded MaxCyte Inc. (NASDAQ:MXCT) from Buy to Neutral on Monday, citing ongoing funding challenges for the company’s cell and gene therapy customers. The stock has declined over 33% in the past week and is currentl... Full story

Yahoo Finance • 2 months ago

Which stocks are moving on Thursday?

Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top gainers and losers in today's session. [topmovers] TOP GAINERS TICKER CHANGE COMMENT IMG [https://www.c... Full story

Yahoo Finance • 2 months ago

Traders are paying attention to the gapping stocks in Thursday's session.

Traders are paying attention to the gapping stocks in Thursday's session. Let's dive into which stocks are experiencing notable gaps. [gap] TOP GAP UP STOCKS TICKER CHANGE COMMENT AVAH [https://www.chartmill.com/stock/quote/A... Full story

Yahoo Finance • 2 months ago

MaxCyte signs platform license agreement with Adicet Bio

* MaxCyte (NASDAQ:MXCT [https://seekingalpha.com/symbol/MXCT]) said on Monday that it has signed a strategic platform license [https://seekingalpha.com/pr/20187448-maxcyte-signs-platform-license-agreement-with-adicet-bio] with Adicet Bio... Full story

Yahoo Finance • 2 months ago

MaxCyte Signs Platform License Agreement with Adicet Bio

MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support development of Adicet’s gamma delta T cell therapy gene edited programs ROCKVILLE, Md., Aug. 04, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leadin... Full story

Yahoo Finance • 2 months ago

MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline

ROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-gen... Full story

Yahoo Finance • 3 months ago

MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025

ROCKVILLE, Md., July 09, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-gen... Full story

Yahoo Finance • 3 months ago

MaxCyte to delist shares from London AIM, maintains Nasdaq listing

MaxCyte, Inc. (NASDAQ:MXCT), currently trading at $2.23 with a market capitalization of $239 million, announced Wednesday that it has applied to the London Stock Exchange (LON:LSEG) to cancel the admission of its common stock from tradin... Full story

Yahoo Finance • 2 years ago

MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing

ROCKVILLE, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization... Full story

Yahoo Finance • 3 years ago

MaxCyte Reports Fourth Quarter and Full Year 2022 Financial Results

MaxCyte, Inc 31% Total Revenue Growth for Full Year 2022 including 26% Core Business Revenue Growth and $4.6 million in Program-related Revenue ROCKVILLE, Md., March 15, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT),... Full story

Yahoo Finance • 3 years ago

MaxCyte Establishes New Scientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology

MaxCyte, Inc MaxCyte’s Scientific Advisory Board will provide guidance to shape the technical direction of the company’s innovation initiatives focused on the discovery, development and manufacturing of next-generation, cell-based medicin... Full story

Yahoo Finance • 3 years ago

Insiders who bought in the last 12 months lose an additional US$55k as MaxCyte, Inc. (LON:MXCT) drops to UK£566m

Insiders who acquired US$166k worth of MaxCyte, Inc.'s (LON:MXCT) stock at an average price of US$8.29 in the past 12 months may be dismayed by the recent 10% price decline. Insiders buy with the expectation to see their investments rise i... Full story

Yahoo Finance • 3 years ago

MaxCyte to Report Third Quarter 2022 Financial Results on November 9, 2022

ROCKVILLE, Md., Oct. 12, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as we... Full story

Yahoo Finance • 3 years ago

Top 10 Stock Picks of Eli Casdin’s Casdin Capital

In this article, we discuss the top 10 stock picks of Eli Casdin's Casdin Capital. If you want to skip our detailed analysis of Casdin's investment philosophy and performance, go directly to Top 5 Stock Picks of Eli Casdin's Casdin Capital... Full story

Yahoo Finance • 3 years ago

MaxCyte to Report Second Quarter 2022 Financial Results on August 10, 2022

GAITHERSBURG, Md., July 15, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as... Full story

Yahoo Finance • 3 years ago

MaxCyte Signs Strategic Platform License with LG Chem to Advance its Allogeneic CAR-T Programs

GAITHERSBURG, Md., July 12, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as... Full story

Yahoo Finance • 3 years ago

MaxCyte to Report First Quarter 2022 Financial Results on May 9, 2022

MaxCyte, Inc GAITHERSBURG, Md., April 20, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-base... Full story